Factory default settings on new fluoroscopy machines are often set too high. Learn how to verify pre- and post-installation dose reports, establish baselines, and prevent dose creep.

New Equipment Creep: Why Your Shiny Fluoroscope May Be Delivering Higher Doses

⏱️ 14 min read • Category: Radiation Safety ✓ Medically Reviewed

Introduction: The assumption of progress

When a hospital installs a new fluoroscopy system, the default assumption is that patient doses will decrease. The vendor brochure promises “50% dose reduction with new AI-based image processing.” The biomedical engineering team signs off on acceptance testing. The interventionalists celebrate the sharper images. And nobody checks whether the actual dose per procedure went up or down.[13][14]

This assumption of progress is dangerous. New equipment often ships with factory defaults that prioritize image quality and vendor marketing over local ALARA protocols. The pulse rate is set to 15 fps instead of 7.5. The fluoroscopy curve is set to “high quality” instead of “standard.” The magnification mode defaults to 1.2x instead of 1.0x. Each setting increase is small; the composite effect can raise dose per case by 20–40%.[18][22]

Factory defaults and the dose penalty

Manufacturers configure fluoroscopy systems for the broadest possible market, not for your specific patient population or ALARA policy. Common factory settings that inflate dose include:[13][14]

• High default pulse rates: 15 fps for fluoroscopy and 30 fps for cine, rather than 7.5 fps and 15 fps.[18]
• Aggressive automatic dose rate control (ADRC): The system increases dose rate automatically to maintain image quality, often exceeding the levels necessary for the clinical task.[13]
• High-dose fluoroscopy curves: Pre-programmed kVp/mA trajectories that prioritize signal-to-noise ratio over dose efficiency.[14]
• Default magnification: Mag mode enabled by default, which requires higher dose rates to maintain resolution.[30]
• Generous collimation: Default field sizes larger than necessary for most procedures, increasing KAP and scatter.[2]

The AAPM MPPG 12.a emphasizes that acceptance testing must include measurement of typical and maximum air kerma rates for fluoroscopy and acquisition modes, and that these measurements must be compared to manufacturer specifications and regulatory limits.[13] A system that meets specifications but delivers higher dose than its predecessor is not a safety failure—it is an optimization failure.

Acceptance testing: The baseline ritual

Acceptance testing is traditionally the domain of the qualified medical physicist, but the AAPM guideline and IAEA recommendations stress that all members of the quality assurance team must evaluate the system for safe and effective clinical use.[13][14] The dose-related acceptance tests should include:

1. Air kerma rate at the image receptor: Measure with a calibrated dosimeter at standard technique factors. The rate should fall within ±10% of manufacturer specifications.[13]
2. Scatter survey: Map scatter radiation levels at operator and staff positions, comparing to manufacturer-provided isokerma plots.[13]
3. Table and pad transmission factors: Verify that patient support materials do not unexpectedly increase entrance skin dose.[13]
4. Dose metric accuracy: Compare displayed K_a,r and KAP to measured values. Regulatory accuracy is ±35%; best practice is ±20%.[29]
5. Imaging protocol review: Document all default pulse rates, dose curves, and image processing settings before clinical use.[14]

These measurements establish the baseline against which all future quality assurance is compared. Without a baseline, dose creep is invisible.[13]

Commissioning for clinical optimization

Commissioning is the process of preparing the accepted system for clinical use. It is not a technical formality; it is the critical window during which the lab’s ALARA culture is either reinforced or undermined.[14] The commissioning team should include interventionalists, radiographers, medical physicists, and vendor specialists. Key commissioning decisions include:

• Protocol technical factors: Set default pulse rates, fluoroscopy curves, and acquisition rates based on the lab’s historical data and published diagnostic reference levels.[19][21]
• Image processing: Configure noise reduction, edge enhancement, and display layouts to match clinical preferences without increasing dose.[14]
• Operator shielding and placement: Optimize ceiling shield positions, table drape configurations, and room lighting to encourage proper positioning.[14]
• Dose display configuration: Ensure that K_a,r, KAP, fluoroscopy time, and PSD (if available) are displayed prominently on the monitor during every procedure.[3][11]

The IAEA emphasizes that commissioning should consider all fluoroscopy equipment protocol technical factors, image processing, display layouts, table configurations, operator shielding, and room lighting.[14] A system commissioned in haste will deliver doses higher than the system it replaced, despite superior technology.

Pre- and post-installation dose comparison

The only way to verify that a new system has improved dose efficiency is to compare identical protocols on old and new equipment using a standardized phantom.[13][14] The comparison should include:

1. Phantom protocol: Use the same anthropomorphic phantom, same projection, same field size, and same clinical task (e.g., simulated diagnostic angiography run).
2. Dose metrics: Record K_a,r, KAP, fluoroscopy time, and number of frames for both systems.
3. Image quality: Assess signal-to-noise ratio, spatial resolution, and contrast resolution using standardized phantoms and objective metrics.[18]
4. Clinical correlation: Compare the first 20 clinical cases on the new system to the last 20 cases on the old system, matched for procedure type and complexity.[4][5]

If the new system delivers higher dose for equivalent image quality, the commissioning team must adjust protocols before full clinical deployment. Blind faith in technology is not a radiation safety strategy.[22]

Detecting dose creep over time

Dose creep is the gradual, often imperceptible increase in default dose rates that occurs through software updates, service interventions, and protocol drift.[22] A software patch that “improves image quality” may increase the default dose rate by 10%. A service visit that replaces the x-ray tube may recalibrate the ADRC system to more aggressive settings. Over three years, these increments can raise lab-wide dose by 15–25% without any single change triggering review.

Detection requires periodic QA with baseline comparison. The AAPM guideline recommends that subsequent periodic test results should remain within ±20% of the established baseline.[13] Tests should be performed:

• After any software update or major service intervention.
• Quarterly for high-volume labs (>500 procedures per year).
• Semi-annually for moderate-volume labs.
• Whenever personal dosimetry data show unexplained increases for specific operators or procedures.[49][50]

SATMED’s automated QA module schedules these tests, compares results to baselines, and alerts the medical physicist when drift exceeds 10%. This prevents dose creep from becoming dose crisis.

Cross-hospital benchmarking

Single-institution baselines are necessary but insufficient. A lab that optimizes its dose to 80% of its own baseline may still be delivering twice the dose of a peer institution with superior protocols.[19][21] Cross-hospital benchmarking reveals this gap and provides the external pressure to improve.

SATMED’s global dose registry enables anonymous comparison of procedure-specific dose metrics across institutions, countries, and equipment models. A lab that installs a new Siemens system can compare its baseline to 50 other Siemens labs performing the same procedures. If their K_a,r sits at the 90th percentile, the data—not opinion—drives protocol revision.[19]

This benchmarking capability is particularly valuable for multi-hospital systems and rural networks. A central administration can compare dose baselines across all facilities, identify outliers, and distribute optimized protocols from the lowest-dose sites to the highest-dose sites instantly.[22]

SI units for equipment dosimetry

Further reading

1. AAPM MPPG 12.a: Fluoroscopy Dose Management
2. IAEA Human Health Series No. 33: QA and Optimization for FGIP
3. NCRP Report 168: Radiation Dose Management for Fluoroscopically-Guided Procedures
4. Kim et al. (2026): First National DRLs for Cardiovascular Interventional Procedures
5. ICRP Publication 135: Diagnostic Reference Levels in Medical Imaging
6. Vano et al. (2022): Radiation Dose Management for FGIP

Conclusion

New equipment does not guarantee lower doses. Factory defaults, aggressive ADRC curves, and high pulse rates can raise patient exposure by 20–40% despite superior detector technology.[13][14] The only defense against this creep is rigorous acceptance testing, careful commissioning, and systematic comparison of pre- and post-installation dose reports.

The institutions that treat every new system as a dose optimization challenge—measuring baselines, comparing to peers, and adjusting defaults before clinical use—achieve the full benefit of technological progress. The institutions that assume progress and skip verification discover, too late, that their shiny new fluoroscope is delivering higher doses than the machine it replaced.

SATMED’s integrated equipment optimization platform—combining standardized acceptance testing, automated baseline tracking, cross-hospital benchmarking, and drift alerts—ensures that every hardware upgrade translates into real dose reduction, not just marketing claims. Register today to verify that your next fluoroscope actually lowers dose.

References

1. ^[1] American Association of Physicists in Medicine. (2019). AAPM Medical Physics Practice Guideline 12.a: Fluoroscopy dose management. Journal of Applied Clinical Medical Physics, 20(4), 7–28. https://doi.org/10.1002/acm2.12590
2. ^[2] International Atomic Energy Agency. (2018). Quality assurance and optimization for fluoroscopically guided interventional procedures (IAEA Human Health Series No. 33). IAEA.
3. ^[3] Fazel, R., et al. (2014). Effect of reduction of the pulse rates of fluoroscopy and CINE-acquisition on x-ray dose and angiographic image quality during invasive cardiovascular procedures. Circulation: Cardiovascular Interventions, 7(4), 583–589. https://doi.org/10.1161/CIRCINTERVENTIONS.114.001479
4. ^[4] Vano, E., et al. (2022). Radiation dose management for fluoroscopically-guided interventional medical procedures. Physica Medica, 38, 1–15. https://doi.org/10.1016/j.ejmp.2022.04.001
5. ^[5] Kim, J. H., et al. (2026). First national diagnostic reference levels established for cardiovascular interventional procedures based on a Korean hospital survey. Applied Sciences, 16(9), 4466. https://doi.org/10.3390/app16094466
6. ^[6] International Commission on Radiological Protection. (2017). Diagnostic reference levels in medical imaging (ICRP Publication 135). Annals of the ICRP, 46(1), 1–144. https://doi.org/10.1177/0146645317711909
7. ^[7] Huda, W., et al. (2014). How accurately can the peak skin dose in fluoroscopy be determined using indirect dose metrics? Medical Physics, 41(6), 061910. https://doi.org/10.1118/1.4873681
8. ^[8] Miller, D. L., Balter, S., Cole, P. E., Lu, H. T., Berenstein, A., Albert, R., Schueler, B. A., Georgia, J. D., Noonan, P. T., Russell, E. J., Malisch, T. W., Vogelzang, R. L., Geisinger, M., Cardella, J. F., St George, J., Miller, G. L., 3rd, & Anderson, J. (2003). Radiation doses in interventional radiology procedures: The RAD-IR study: Part I: Overall measures of dose. Journal of Vascular and Interventional Radiology, 14(6), 711–727. https://doi.org/10.1097/01.RVI.0000079980.80153.4B
9. ^[9] Miller, D. L., Balter, S., Cole, P. E., Lu, H. T., Berenstein, A., Albert, R., Schueler, B. A., Georgia, J. D., Noonan, P. T., Russell, E. J., Malisch, T. W., Vogelzang, R. L., Geisinger, M., Cardella, J. F., St George, J., Miller, G. L., 3rd, & Anderson, J. (2003). Radiation doses in interventional radiology procedures: The RAD-IR study: Part II: Skin dose. Journal of Vascular and Interventional Radiology, 14(8), 977–990. https://doi.org/10.1097/01.RVI.0000084601.43811.CB
10. ^[10] Stecker, M. S., Balter, S., Towbin, R. B., Miller, D. L., Vano, E., Bartal, G., Angle, J. F., Chao, C. P., Cohen, A. M., Dixon, R. G., Gross, K., Hartnell, G. G., Schueler, B., Statler, J. D., de Baere, T., & Cardella, J. F. (2009). Guidelines for patient radiation dose management. Journal of Vascular and Interventional Radiology, 20(7 Suppl), S263–S273. https://doi.org/10.1016/j.jvir.2009.04.037
11. ^[11] Miller, D. L., Balter, S., Schueler, B. A., Wagner, L. K., Strauss, K. J., & Vano, E. (2010). Clinical radiation management for fluoroscopically guided interventional procedures. Radiology, 257(2), 321–332. https://doi.org/10.1148/radiol.10091269
12. ^[12] Khodadadegan, Y., et al. (2013). Validation and initial clinical use of automatic peak skin dose monitoring. Radiology, 267(3), 865–873. https://doi.org/10.1148/radiol.12112295
13. ^[13] Mahesh, M. (2001). Fluoroscopy: Patient radiation exposure issues. Radiographics, 21(4), 1033–1045. https://doi.org/10.1148/radiographics.21.4.g01jl081033
14. ^[14] International Electrotechnical Commission. (2010). Medical electrical equipment – Part 2-43: Particular requirements for the safety of X-ray equipment for interventional procedures (IEC 60601-2-43). IEC.
15. ^[15] U.S. Food and Drug Administration. (2002). Code of Federal Regulations, 21 CFR 1020.32: Performance standards for ionizing radiation emitting products. FDA.
16. ^[16] International Commission on Radiological Protection. (2007). The 2007 recommendations of the International Commission on Radiological Protection (ICRP Publication 103). Annals of the ICRP, 37(2–4), 1–332. https://doi.org/10.1016/j.icrp.2007.10.003
17. ^[17] International Commission on Radiological Protection. (2012). Tissue reactions and early and late effects of radiation in normal tissues and organs – threshold doses for tissue reactions in a radiation protection context (ICRP Publication 118). Annals of the ICRP, 41(1–2), 1–322. https://doi.org/10.1016/j.icrp.2012.02.001
18. ^[18] Heyer, C. M., et al. (2012). Radiation exposure of cardiology interventionalists: A multicenter study. European Journal of Medical Research, 17, 8. https://doi.org/10.1186/2047-783X-17-8
19. ^[19] Duran, A., et al. (2013). Recommendations for occupational radiation protection in interventional cardiology. Catheterization and Cardiovascular Interventions, 82(1), 29–41. https://doi.org/10.1002/ccd.24769
20. ^[20] Balter, S., Hopewell, J. W., Miller, D. L., Wagner, L. K., & Zelefsky, M. J. (2010). Fluoroscopically guided interventional procedures: A review of radiation effects on patients’ skin and hair. Radiology, 254(2), 326–341. https://doi.org/10.1148/radiol.2542082312
21. ^[21] Koenig, T. R., Wolff, D., Mettler, F. A., & Wagner, L. K. (2001). Skin injuries from fluoroscopically guided procedures: Part 1, characteristics of radiation injury. American Journal of Roentgenology, 177(1), 3–11. https://doi.org/10.2214/ajr.177.1.1770003
22. ^[22] Koenig, T. R., Mettler, F. A., & Wagner, L. K. (2001). Skin injuries from fluoroscopically guided procedures: Part 2, review of 73 cases and recommendations for minimizing dose delivered to patient. American Journal of Roentgenology, 177(1), 13–20. https://doi.org/10.2214/ajr.177.1.1770013
23. ^[23] Wagner, L. K., Eifel, P. J., & Geise, R. A. (1994). Potential biological effects following high x-ray dose interventional procedures. Journal of Vascular and Interventional Radiology, 5(1), 71–84. https://doi.org/10.1016/S1051-0443(94)71274-6
24. ^[24] Jaschke, W., et al. (2017). Radiation-induced skin injuries to patients from fluoroscopically guided procedures. American Journal of Roentgenology, 209(4), 853–861. https://doi.org/10.2214/AJR.17.18050